Article

Bromodomains as therapeutic targets

Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK.
Expert Reviews in Molecular Medicine (Impact Factor: 5.91). 10/2011; 13:e29. DOI: 10.1017/S1462399411001992
Source: PubMed

ABSTRACT Acetylation of lysine residues is a post-translational modification with broad relevance to cellular signalling and disease biology. Enzymes that 'write' (histone acetyltransferases, HATs) and 'erase' (histone deacetylases, HDACs) acetylation sites are an area of extensive research in current drug development, but very few potent inhibitors that modulate the 'reading process' mediated by acetyl lysines have been described. The principal readers of ɛ-N-acetyl lysine (K(ac)) marks are bromodomains (BRDs), which are a diverse family of evolutionary conserved protein-interaction modules. The conserved BRD fold contains a deep, largely hydrophobic acetyl lysine binding site, which represents an attractive pocket for the development of small, pharmaceutically active molecules. Proteins that contain BRDs have been implicated in the development of a large variety of diseases. Recently, two highly potent and selective inhibitors that target BRDs of the BET (bromodomains and extra-terminal) family provided compelling data supporting targeting of these BRDs in inflammation and in an aggressive type of squamous cell carcinoma. It is likely that BRDs will emerge alongside HATs and HDACs as interesting targets for drug development for the large number of diseases that are caused by aberrant acetylation of lysine residues.

1 Bookmark
 · 
211 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herein we describe the design and synthesis of a dual active histone deacetylase (HDAC)/bromodomain and extra terminal (BET) small molecule tool inhibitor, DUAL946 (1). Exploiting our extensive epigenetic toolbox, we achieved the functionalisation of a BET active tetrahydroquinoline (THQ) core, with a hydroxamic acid HDAC inhibitor (HDACi) motif. Dual inhibition of BET and HDAC proteins was confirmed by in vitro biochemical and biophysical testing and through chemoproteomic competition experiments in cell lysates. This activity was translated into potent cellular activity in both immune and cancer cells.
    Medicinal Chemistry Communication 01/2014; 5(3):342. DOI:10.1039/c3md00285c · 2.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiotherapy treats cancer by inducing DNA double strand breaks (DSBs) in tumor cells using ionizing radiation. However, DNA repair in tumor cells often leads to radioresistance and unsuccessful outcome. Inhibition of DNA repair by targeting repair proteins can increase radiosensitivity of tumor cells. The BRG1 chromatin remodeling enzyme assists DSB repair by stimulating γ-H2AX formation and BRG1 binding to acetylated histones at DSBs via bromodomain (BRD) is critical for this activity. Here, we show that ectopic expression of BRG1-BRD inhibited γ-H2AX and DSB repair after irradiation and increased the radiosensitivity in various human cancer cells, including HT29 colon cancer. Dimerization of BRG1-BRD, increasing its chromatin binding affinity, aggravated the defects in γ-H2AX and DSB repair and further enhanced the radiosensitivity. While little affecting the upstream ATM activation, BRG1-BRD in irradiated HT29 cells inhibited the recruitment of 53BP1 to damaged chromatin, the downstream event of γ-H2AX, and compromised the G2/M checkpoint and increased apoptosis. Importantly, in a xenograft mouse model, BRG1-BRD increased the radiosensitivity of HT29 tumors, which was further enhanced by dimerization. These data suggest that BRG1-BRD radiosensitizes tumor cells by a dominant negative activity against BRG1, which disrupts γ-H2AX and its downstream 53BP1 pathways, leading to inefficient DNA repair, G2/M checkpoint defect and increased apoptosis. This work therefore identifies BRG1-BRD as a novel tumor radiosensitizer and its action mechanism, providing the first example for chromatin remodeler as a target for improving cancer radiotherapy. Copyright © 2014, American Association for Cancer Research.
    Molecular Cancer Therapeutics 12/2014; 14(2). DOI:10.1158/1535-7163.MCT-14-0372 · 5.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bromodomains (BRDs) are protein interaction modules that selectively recognize ε-N-acetylated lysine residues. BRDs are present in diverse proteins that play key functions in chromatin organization and regulation of gene transcription. Aberrant transcription is a hallmark of many diseases in particular cancer and inflammation. The complexity of molecular processes regulating gene transcription identified transcriptional regulators as interesting targets for the development of specific chemical tool molecules (chemical probes) that help to understand the molecular mechanisms of transcription and to explore the potential of BRD mediated interactions as sites for pharmaceutical intervention. Recently a number of highly specific inhibitors have been developed against the BET (bromo and extra terminal) family of bromodomains. The availability of selective BRD inhibitors had a significant impact on the validation of bromodomain-containing proteins as targets for drug development and for our understanding of the biological roles of these proteins. In this review we will summarize the discovery of BET bromodomain inhibitors and their roles in target validation.
    Medicinal Chemistry Communication 03/2014; 5(3):288. DOI:10.1039/c3md00291h · 2.63 Impact Factor

Full-text (3 Sources)

Download
58 Downloads
Available from
Jun 1, 2014